Results 111 to 120 of about 36,256 (261)

482TiP Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE [PDF]

, 2016
Tony Mok, Peter Schmid, Gilberto de Castro, K. Syrigos, Claudio Martín, Nobuyuki Yamamoto, Osvaldo Rudy Aren, Óscar Arrieta, Maya Gottfried, Abdul Rahman Jazieh, Rodryg Ramlau, Constanta Timcheva, Leonardo Trani   +12 more
openalex   +1 more source

Supplementary Data from Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer

, 2023
Kim Blenman, Michał Marczyk, Thomas Karn, Qing Tao, Xiaotong Li, Vignesh Gunasekharan, Vesal Yaghoobi, Yalai Bai, Eiman Ibrahim, Tristen Park, Andrea Silber, Denise M. Wolf, Emily Reisenbichler, Carsten Denkert, Bruno V. Sinn, Mariya Rozenblit, Julia Foldi, David L. Rimm, Sibylle Loibl, Lajos Pusztai   +19 more
openalex   +1 more source

A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report [PDF]

, 2021
Svitlana Manko, Benoît Côté, Nathalie Provost   +2 more
openalex   +1 more source

Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival

International Journal of Cancer, Volume 158, Issue 5, Page 1292-1301, 1 March 2026.
What's New? Patients with esophageal or gastroesophageal junction (GEJ) cancer with residual disease after treatment with neoadjuvant chemoradiotherapy (nCRT) and resection frequently experience poor survival. Improvements in outcome, however, may be possible using adjuvant treatment with nivolumab.
Rob H. A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas Wijnhoven, Mark I. van Berge Henegouwen, Peter S. N. van Rossum, Sarah Derks, Bianca Mostert, Nadia Haj Mohammad, Hanneke W. M. van Laarhoven   +9 more
wiley   +1 more source

Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Aim Integration of locoregional treatments (LRTs) with atezolizumab plus bevacizumab (atezo/bev) has improved treatment outcomes, enabling an increasing number of patients with unresectable hepatocellular carcinoma (HCC) to achieve a complete response (CR). A comprehensive analysis of recurrence following CR may provide insights into prognosis.
Tasuku Nakabori, Masaki Kawabata, Kaori Mukai, Hidenari Hongyo, Noboru Maeda, Makiko Urabe, Yugo Kai, Ryoji Takada, Kenji Ikezawa, Hiroshi Wada, Kunihito Gotoh, Kazuyoshi Ohkawa   +11 more
wiley   +1 more source

Data from Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab

, 2023
Rajiv Raja, Michael Kuziora, Philip Z. Brohawn, Brandon W. Higgs, Ashok Gupta, Phillip A. Dennis, Koustubh Ranade   +6 more
openalex   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Nivolumab plus ipilimumab has shown survival benefits as first‐line treatment for unresectable hepatocellular carcinoma (HCC) but their high cost raises concerns about value. This study assessed the cost‐effectiveness of nivolumab plus ipilimumab compared with lenvatinib or sorafenib from a United States (US) health care payer ...
Jiefeng Luo, Zhengxiong Li, Jun Ge, Sizhen Cai, Xinyi Mo, Wensheng Liu, Chengxia Gui, Qiong Du, Jiyong Liu   +8 more
wiley   +1 more source

Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele

Cancer, Volume 132, Issue 3, 1 February 2026.
ABSTRACT Background While immune checkpoint inhibitors (ICIs) have shown significant efficacy, a common side effect is cutaneous immune‐related adverse events (irAEs). This study focuses on exploring the association between specific human leukocyte antigen (HLA) alleles and the development of cutaneous irAEs in melanoma patients undergoing ICI ...
Mckenzie DiLeo, Samantha Oglesby, Cheuk Hong Leung, Kristen E. Pauken, Sahira Farooq, Lauren E. Haydu, Shelby L. Kubicki, Rebeca Martinez, Macartney Welborn, Sana Zahiruddin, Jun Zou, Kai Cao, Anisha B. Patel   +12 more
wiley   +1 more source

Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

, 2023
Nabendu Pore, Song Wu, Nathan Standifer, Maria Jure‐Kunkel, Melissa de los Reyes, Yashaswi Shrestha, Rebecca Halpin, Raymond Rothstein, Kathy Mulgrew, Stephen Blackmore, Philip Martin, John Meekin, Matthew Griffin, Ina Bisha, Theresa A. Proia, Ricardo J. Miragaia, Ronald Herbst, Ashok Gupta, Shaad E. Abdullah, Rajiv Raja, Melanie M. Frigault, J. Carl Barrett, Phillip A. Dennis, Maria Libera Ascierto, Michael D. Oberst   +24 more
openalex   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source